medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2013, Number 3

<< Back Next >>

Biotecnol Apl 2013; 30 (3)

Formulation development of a recombinant Streptokinase suppository for hemorrhoids treatment

Aguilera A, Bermudez Y, Martínez E, Marrero MA, Muñoz L, Páez R, Tamargo B, Hernández LF, García O

Language: English
References: 34
Page: 182-186
PDF size: 165.77 Kb.


ABSTRACT

Recombinant Streptokinase (rSK) is a protein of bacterial origin currently used in the treatment of acute myocardial infarction. Its thrombolytic and anti-inflammatory action makes it attractive for the treatment of hemorrhoids. In this work the influence of absorption enhancer, preservative and emulsifiers on rSK stability was accessed by determining its biological activity under stress conditions. According to the results obtained, were selected as excipients for the formulation: Sodium salicylate as enhancer and anti-inflammatory agent, thimerosal as preservative, Span 60 as emulsifier and Witepsol W25 as suppository base and 100 000 IU per gram of suppository for stability study. Afterwards, three lots at pilot scale were manufactured, packed in aluminum blister shell and stored at 5 ± 3 ºC. Immediately after preparation, the samples were evaluated at months 0, 3, 6, 9, 12 and 18 having into account the physical, chemical and biological properties. The stability study demonstrated that the formulation containing rSK as active pharmaceutical ingredient was stable during 18 months under refrigerated conditions.


REFERENCES

  1. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classifi cation. Nat Rev Drug Discov. 2008;7:21-39.

  2. Jitendra P, Sharma K, Sumedha B, Arunabha B. Noninvasive routes of proteins and peptides drug delivery. Indian J Pharm Sci. 2011;73(4):367-75.

  3. Chin CM, Gutierrez M, Still JG, Kosutic G. Pharmacokinetics of modified oral calcitonin product in healthy volunteers. Pharmacotherapy. 2004;24(8):994-1001.

  4. Goto T, Morishita M, Nishimura K Nakanishi M, Kato A, Ehara J, et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res. 2006; 23:384-91.

  5. Jitendra J, Shivendra KD, Yusuf AJ. A buccal drug delivery system. Int J Pharm Res Sci.2013:513-31.

  6. Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler. 2003;9(4):342-8.

  7. Sikri NA, Bardia A. History of streptokinase use in acute myocardial infarction. Tex Heart Inst J. 2007;34(3):318-27.

  8. Rosenstein E. Specialty Pharmaceutical Dictionary. 41th ed. Distrito Federal: PLM de México S.A. de C.V., 1995.

  9. Oliven A, Gidron E. Orally and rectally administered Streptokinase. Investigation of its absorption and activity. Pharmacology. 1981;22:135-8.

  10. Sánchez C, Chinn BT. Hemorroids. Clin Colon Rectal Surg. 2011;24(1):5-13.

  11. Hernández L, Rodríguez P , Castro A, Serrano R, Rodriguez MP, Rubiera M, et al. Determination of streptokinase activity by quantitative assay. Biotecnol Apl. 1990;7: 153-60.

  12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227: 680-5.

  13. The United States Pharmacopeia, 30th, and The National Formulary, 25th ed. Rockville, MD: The United States Pharmacopeial Convention; 2007.

  14. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use ICH harmonized tripartite guideline evaluation for stability data Q1E current step 4 version dated 6 February. 2003. Available from: http://www.ich. org/fi leadmin/Public_Web_Site/ICH_Products/ Guidelines/Quality/Q1E/Step4/ Q1E_Guideline.pdf

  15. Sigarroa A. Biometría y diseño experimental. La Habana: Pueblo y Educación; 1985.

  16. Shembale Al, Borole DK and Lohiya RT. Useful permeation enhancers for transdermal drug delivery. Int J Pharm Res Dev. 2010;2:1-6.

  17. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery system. Trop J Pharm Res. 2009;8(2):173-9.

  18. Fihn BM, Jodal M. Permeability of the proximal and distal rat colon crypt and surface epithelium to hydrophilic molecules. Pfl ugers Arch. 2001;441:656-62.

  19. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst. 1996;13(1-2):85-184.

  20. Marrero MA, Aguilera A, Gonzalez L, Martinez E, Torrez B, Cosme K, et al, inventors; Center for Genetic Engineering and Biotechnology, assignee. Formulations for the rectal administration of thrombolyticallyactive agents. United States Patent US 20070166298. 2003 Dec 22..

  21. Matuli M, Brdar B. Induction of urokinase- type plasminogen Activator. Food Technol Biotechnol. 2001;39:5-11.

  22. Sonia MG, Burdocka GA, Taylorb SL, Greenbergc NA. Safety assessment of propyl paraben: a review of the published literature. Food Chem Toxicol. 2001;6: 513-32.

  23. Tukker J. Rectal and vaginal drug delivery. In: Aulton ME, editor. Pharmaceutics, the science of dosage form design. Edinburgh: Churchill Livingstone. 2009; p. 534-43.

  24. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of confl icting data and opinions. Otolaryngol Head Neck Surg. 2004;130(1):131-41.

  25. Eierman HJ. Cosmetic product preservation: safety and regulatory issues. In: Kabara JJ, editor. Cosmetic and Drug preservation: principles and practice. New York: Marcel Dekker. 1984; p. 559-69.

  26. Orenstein WA, Paulson JA, Brady MT, Cooper LZ, Seib K. Global vaccination recommendations and thimerosal. Pediatrics. 2013;131(1):149-51.

  27. Wadhwa J, Nair A, Kumria R. Emulsion forming drug delivery system for lipophilic drugs. Acta Pol Pharm. 2012;69(2): 179-91.

  28. Akhtar N, Rehman MV, Khan HS, Rasool F. Permeation enhancing effect of Polysorbate 20 and 80 on the in vitro percutaneous absorption of L-Ascorbic acid. Trop J Pharm Res. 2011;101(3):281-8.

  29. Samita S, Kumar HSL, Aggarwal G. Surfactants as skin permeation enhancers for transdermal drug delivery. Int J Nat Prod Sci. 2012;1(Special issue):10.

  30. El-Majri M, Sharma R. Formulation and evaluation of piroxicam suppositories. Int J Drug Deliv. 2010;2:108-12.

  31. Britsh Pharmacopeia 2004. London: British Pharmacopoeia Comission Offi ce; 2004.

  32. Lopez M, Ruiz LL, Reyes M. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin. J Clin Pharm Ther. 2004:29:367-73.

  33. Hernández L, Marrero MA. Estreptoquinasa: a propósito de un agente trombolítico patentado en Cuba. Biotecnol Apl. 2005;22(1):182-90.

  34. Quintero L, Hernández-Bernal F, Acelia M, López M, Barcelona S, Ibargollín R, et al. Initial evidence of safety and clinical effect of recombinant streptokinase suppository in acute hemorrhoidal disease. Open, proof-of-concept, pilot trial. Biotecnol Apl. 2010;27:277-80.




2020     |     www.medigraphic.com